ESMO21

Aprea Therapeutics Stock Jumps After Eprenetapopt Combo Data Presentation At ESMO
AstraZeneca's Enhertu Posts Substantial Clinical Benefit Over Roche's Kadcyla In Breast Cancer Trials
Syros Posts Updated Data From CDK7 Inhibitor In Various Solid Tumor Settings
AstraZeneca's Enhertu Posts Substantial Clinical Benefit Over Roche's Kadcyla In Breast Cancer Trials
Syros Posts Updated Data From CDK7 Inhibitor In Various Solid Tumor Settings
Exelixis's Cabometyx Scores FDA Nod In Differentiated Thyroid Cancer; ESMO Presentation
Why Are BeyondSpring's Shares Plunging Today?

ESMO21 Recent News

Mirati Unveils Long-term Survival Data For Sitravatinib/Nivolumab Combo In Lung Cancer Patients
|
Mirati Posts Adagrasib Data In KRAS-Mutated Lung Cancer, FDA Filing Now On The Cards
|
Mirati Showcases New KRAS Drug Data In Colorectal Cancer At ESMO
|
Verastem Shares Are Trading Higher On Encouraging Combo Therapy Data At ESMO Presentation
|
Seagen, Genmab Present Tisotumab Vedotin Combo Data In Cervical Cancer
|
Sanofi, Regeneron, Share Competitive Libtayo Survival Data in 1L NSCLC
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (NASDAQ: SNY) hope to expand Libtayo into a broader population with a chemo combo regimen. 
|
Janssen Shares Erdafitinib Combo Therapy Data In Bladder Cancer
|
TCR2 Therapeutics Stock Plunges On Safety Signals From Gavo-cel Solid Tumor Trial
TCR2 Therapeutics Inc (NASDAQ: TCRR) stock dropped to a 52-week low after interim results from the ongoing Phase 1 portion of the gavo-cel Phase 1/2 trial for mesothelin-expressing solid tumors. 
|
Deciphera Presents New Data Across Pipeline At ESMO Congress
|
What Is Happening With Innate Pharma Stock On Friday?
|
Gritstone Presents Data From Individualized Neoantigen Immunotherapy In Colorectal Cancer
|
Junshi Biosciences, Coherus Share Toripalimab Survival Data In Esophageal Cancer
Shanghai Junshi Biosciences Co Ltd and Coherus BioSciences Inc (NASDAQ: CHRS) announced interim results from the Phase 3 JUPITER-06 trial.
|
Agenus' Combo Therapy Trial Shows Higher Responses In Cervical Cancer
|
Ayala Pharma Unveils New Interim Data From Rare Cancer Trial With AL101
|
NGM Bio Presents Preliminary Data From NGM120 Solid Tumor Trial
|
MacroGenics Shares Fall After MGC018 Data Fails To Impress At ESMO Presentation
MacroGenics Inc (NASDAQ: MGNX) 
|
Bristol Myers Touts 5-Year Kidney Cancer Data For Opdivo-Yervoy Combo Therapy
|
Gilead Churns Out Additional Trodelvy Data
|

Connect With Us

instagramlinkedinyoutube

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell

© 2025 Benzinga | All Rights Reserved